AMS Capital Ltda purchased a new stake in Allergan plc (NYSE:AGN) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 15,000 shares of the company’s stock, valued at approximately $2,454,000. Allergan comprises 1.0% of AMS Capital Ltda’s portfolio, making the stock its 17th biggest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of AGN. Edgewood Management LLC increased its holdings in shares of Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after acquiring an additional 869,248 shares during the last quarter. Baupost Group LLC MA increased its holdings in shares of Allergan by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after acquiring an additional 531,600 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in Allergan by 4,852.6% during the 3rd quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock valued at $103,108,000 after purchasing an additional 492,930 shares during the period. Point72 Asset Management L.P. acquired a new position in Allergan during the 3rd quarter valued at approximately $92,182,000. Finally, Polaris Capital Management LLC boosted its position in Allergan by 315.4% during the 4th quarter. Polaris Capital Management LLC now owns 500,200 shares of the company’s stock valued at $37,195,000 after purchasing an additional 379,781 shares during the period. Institutional investors and hedge funds own 79.76% of the company’s stock.

Allergan plc (NYSE AGN) opened at $158.72 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04. The stock has a market capitalization of $54,030.00, a price-to-earnings ratio of -13.24, a price-to-earnings-growth ratio of 1.17 and a beta of 1.19. Allergan plc has a 12-month low of $156.11 and a 12-month high of $256.80.

Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. The business had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.90 earnings per share. sell-side analysts expect that Allergan plc will post 15.56 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a $0.72 dividend. This is a positive change from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.81%. Allergan’s dividend payout ratio is -23.35%.

AGN has been the subject of a number of analyst reports. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Deutsche Bank set a $251.00 price objective on Allergan and gave the company a “buy” rating in a research report on Tuesday, October 17th. TheStreet lowered Allergan from a “c-” rating to a “d+” rating in a research report on Monday, December 4th. Morgan Stanley set a $200.00 price objective on Allergan and gave the company a “buy” rating in a research report on Wednesday, December 6th. Finally, Credit Suisse Group set a $243.00 price objective on Allergan and gave the company an “outperform” rating in a research report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $227.23.

In other news, Chairman Brent L. Saunders acquired 4,600 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average price of $164.74 per share, for a total transaction of $757,804.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Chris W. Bodine acquired 3,030 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was purchased at an average price of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 17,630 shares of company stock valued at $2,890,057. Insiders own 0.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “AMS Capital Ltda Purchases Shares of 15,000 Allergan plc (AGN)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/02/14/ams-capital-ltda-purchases-shares-of-15000-allergan-plc-agn.html.

Allergan Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.